Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

Top Idea
|
|
About: Ironwood Pharmaceuticals, Inc. (IRWD), Includes: AGN, BIIB, MNK, SGYP-OLD
by: JV Biotech
This article is exclusive for subscribers.
JV Biotech
Long/short equity, special situations, biotech, small-cap
Summary

Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.

While Ironwood's key drug Linzess is bringing in substantial revenues, its other approved products have shown limited sales. Its pipeline addresses attractive but competitive indications.

Ironwood's management was under pressure in April after biotech activist investor Alex Denner of Sarissa Capital sought a seat on the board of directors.

In May, Ironwood announced that it would separate into two companies: A commercial company focused on its existing disease areas, and an R&D company focused on rare diseases.

This separation should be positive for shareholders - not only from a financial standpoint but also because it might replicate Denner's success at Bioverativ.

Ironwood Pharmaceuticals (IRWD) recently came under pressure as Dr. Alex Denner of activist hedge fund Sarissa Capital attempted to secure a seat on the board of directors. While he was unsuccessful in this